FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and concerns a method for production of "Mobilan (M-VM3)" preparation. During updating developed following stable parameters of the production process: batch volume is 1,500 flasks, time of production is 18-22 days, total consumption of the nutrient medium is 44 l, the volume of virus-containing suspension of M-VM3 is 25 l, density of cells during infection in range from 0.8×106 to 1×106 cl/ml; time for gathering cells is on third day (approximately 72 h); temperature during infection is 36 °C, multiplicity of infection 5-10 PFU/cl, total concentration of viral construct at collection is 8×108 PFU/ml.
EFFECT: invention optimises production, increase its profitability, making optimum ratio of production time/amount of produced/amount spent on production.
1 cl, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PRODUCTION OF RECOMBINANT PSEUDOADENOVIRUS PARTICLES CONCENTRATE, EXPRESSING HEMAGGLUTININ GENE OF INFLUENZA A/CALIFORNIA/07/2009(H1N1) | 2015 |
|
RU2614127C2 |
METHOD FOR MAKING RECOMBINANT ADENOVIRUS PREPARATION CHARACTERISED BY LOWER RATIO OF PHYSICAL AND INFECTIOUS VIRAL PARTICLES, AND GENETICALLY THERAPEUTIC DRUG PREPARATION PRODUCED BY SUCH METHOD | 2009 |
|
RU2443779C2 |
ANTI-TUMOR EFFECTS OF A VIRAL VECTOR ENCODING A TOLL-LIKE RECEPTOR AND A TOLL-LIKE RECEPTOR AGONIST | 2017 |
|
RU2741228C2 |
METHOD FOR PURIFYING MAMMALIAN AND HUMAN RECOMBINANT ADENOVIRUSES | 2011 |
|
RU2465327C1 |
METHOD OF OBTAINING INACTIVATED VACCINE AGAINST COVID-19 AND VACCINE OBTAINED BY METHOD | 2023 |
|
RU2810740C1 |
RECOMBINANT PSEUDO-ADENOVIRAL PARTICLE STRAIN EXPRESSING THE CHLAMYDIA TRACHOMATIS CHIMERIC GENE MBL-CT666, A METHOD FOR PREPARING IT, AN IMMUNOGENIC COMPOSITION FOR PROTECTION AGAINST HUMAN UROGENITAL CHLAMYDIOSIS | 2019 |
|
RU2721123C1 |
WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
SYSTEM FOR STIMULATION OF GENES EXPRESSION AND VECTOR CONTAINING SAID SYSTEM | 2010 |
|
RU2577971C2 |
AGENTS AND METHOD OF PRODUCING VIRAL VECTORS AND VERSIONS OF THEIR USE | 2018 |
|
RU2818529C2 |
DRUG COMBINATION FOR GENE-IMMUNE THERAPY | 2022 |
|
RU2792683C1 |
Authors
Dates
2016-07-10—Published
2015-06-19—Filed